Article Text

Download PDFPDF

Statistics from


Addolorato G, Leggio L, Ferrulli A, . Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet 2007;370:1915–22.

At all stages of alcoholic liver disease (including decompensated cirrhosis) abstinence leads to substantially better clinical outcome compared with any other interventions. However, a variety of measures aimed at achieving and maintaining abstinence have had limited success.

Baclofen, a gamma aminobutyric acid (GABA) B-receptor agonist has the potential to reduce craving in patients who are alcohol-dependent. Addolorato et al randomised 84 patients with liver cirrhosis who were alcohol-dependent to either oral baclofen treatment or placebo for 12 weeks. Of 42 patients allocated baclofen, 30 (71%) achieved and maintained abstinence compared with 12 (29%) of 42 assigned to the placebo group (odds ratio 6.3; 95% CI 2.4 to 6.1; p  =  0.0001). There were more dropouts (termination of treatment) in the placebo group (13/42 (31%)) than in those receiving baclofen (6/42 (14%); p  =  0.12). Cumulative abstinence duration was two-fold higher in patients allocated baclofen than in those assigned to the placebo group (mean 62.8 vs 30.8 days; p  =  0.001). Despite the association of GABA A-receptor ligands with hepatic encephalopathy, baclofen was well tolerated and no hepatic adverse events were …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.